An observational study in Critical Limb Ischemia, sponsored by IRCCS Policlinico S. Donato. Recruiting at 1 site in Italy. Open to participants aged 40 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-11-05.
Sponsored by IRCCS Policlinico S. Donato · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 24 studies in Chronic Limb-Threatening Ischemia with a site in Italy — 5 open to participants now, 5 under way, none of them phase 3. Chronic Limb-Threatening Ischemia · Italy.
Among the 24 studies in Chronic Limb-Threatening Ischemia with a site in Italy, this one is the 10th largest by planned enrollment of the 10 observational ones that give a count, is one of 2 that started in 2016, is one of 10 observational ones, and was the 22nd registered.
359 studies on the registry are indexed under Chronic Limb-Threatening Ischemia; 73 are open to participants now.
Browse Chronic Limb-Threatening Ischemia studies →5 of the 24 studies in Chronic Limb-Threatening Ischemia with a site in Italy are open now. Recruiting first, the newest first:
I.R.C.C.S Ospedale Galeazzi-Sant'Ambrogio · Sites in Italy
Ages 18+
Maria Cecilia Hospital · Sites in Italy
Ages 18+
Biotyx Medical (Shenzhen) Co., Ltd. · Sites in Italy
Ages 18–85
Azienda Ospedaliera Universitaria Senese · Sites in Italy
Ages 18+
A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →
Of the 51 Chronic Limb-Threatening Ischemia studies recruiting now, 35 (69%) set no upper age limit and 2 (4%) stop at 75 or younger; 3 take children under 18; 6 take healthy volunteers.
This study: 40 Years to 85 Years · all sexes.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
24 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 3 · Phase 3 3 · Phase 4 1
First in 2002; this study’s year is marked. 2 started in 2016.
This study's planned enrollment of 80 is below the median of 111 across 104 observational studies indexed under Chronic Limb-Threatening Ischemia.
Median enrollment 65 across the 14 interventional studies, 161 across the 10 observational. Of the 14 that completed or were terminated, 3 (21%) have results posted.
This tab as a report to print or save as PDF → With an account.
7 of 24 have an industry lead sponsor. The 10 most frequent:
IRCCS Policlinico S. Donato is the lead sponsor of 105 studies on the registry; 53 are open to participants now.
IRCCS Policlinico S. Donato has 1 study filed under Chronic Limb-Threatening Ischemia — fewer than ten, so there is no comparison to draw.
2 of the studies in Chronic Limb-Threatening Ischemia with a site in Italy that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07588295Maria Cecilia HospitalLocal And Systemic Macrophage Activation in Coronary and Peripheral Artery Disease | 2026-12 |
| NCT06066268IRCCS Policlinico S. DonatomiRNAs in Critical Limb Ischemia (miRNACLI) | 2027-01-31 |
Add all 2 to your calendar (.ics) → With an account.
Among the 24 studies in Chronic Limb-Threatening Ischemia with a site in Italy, from their registry updates:
This tab as a report to print or save as PDF → With an account.
For the present study, 40 patients affected by critical limb ischemia of different severity will be enrolled: patients affected by critical limb ischemia undergoing subgenual femoropopliteal bypass; patients suffering from terminal ischemia causing gangrene and therefore undergoing major amputation of the lower limb. Biopsies from the first 20 enrolled patients will be used for miRNA profiling. The total of 40 biopsies obtained from all enrolled patients will instead be used for the validation of the miRNAs identified in the profiling.
The results obtained will be compared with those obtained in 40 control patients affected by infrarenal abdominal aortic aneurysm (AAA) undergoing endovascular exclusion surgery (EVAR) of the AAA without any ischemia of the lower limbs. Also in this case the biopsies of the first 20 control patients enrolled will be used for miRNA profiling. The total of 40 biopsies obtained from all control patients will instead be used for the validation of the miRNAs identified in the profiling. A total of 80 patients (40 cases and 40 controls) will be enrolled.
The analyzes of the expression of miRNAs and the RISC complex will be carried out on fragments of skeletal muscle taken from different sites depending on whether they are cases or controls.
Cases:
Controls:
The analyzes of the expression of circulating miRNAs will be carried out on 2 7 ml tubes of peripheral venous blood, taken before the surgical incision from the same cases and controls described in the previous point.
Critical limb ischemia patients
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Cases:
Controls:
Exclusion Criteria:
1)Critical limb ischemia (CLI): * Patients suffering from CLI undergoing lower limb revascularization via subgenual femoropopliteal bypass. muscle biopsies willbe taken. * Patients suffering from terminal CLI and/or gangrene of the lower limb undergoing thigh amputation. Muscle biopsies will be taken. * Patients suffering from terminal CLI and/or gangrene of the lower limb undergoing leg amputation. Muscle biopsies will be taken.
Diagnostic Test: Critical limb ischemia: analysis of RNAs
2)Controls: patients affected by infrarenal abdominal aortic aneurysm (AAA) free from CLI, affected and not affected by type 2 diabetes mellitus, undergoing endovascular exclusion surgery of the AAA (EVAR), similar by age and sex to CLI patients. Sartorius muscle biopsies will be taken.
Diagnostic Test: Controls: analysis of RNAs
analysis of miRNA expression levels
analysis of miRNAs expression levels
Identification of potentially pathogenic miRNAs in CLI and related target mRNAs.
Identify miRNAs and their targets that directly interact with the RNA Induced Silencing Complex (RISC) in muscle biopsies obtained from CLI patients.
Time frame: 1 year to 10 years
Identification of disease biomarkers
Identify plasma miRNAs to be used as disease biomarkers that can be used to assess disease status and severity with a minimally invasive procedure.
Time frame: 1 year to 10 years
Started May 2016 (actual). Primary completion is estimated for Jan 2027, 128 months after the start.
Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 5, 2026: primary completion May 2026 → Jan 2027 and completion May 2026 → Jan 2027.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Chronic Limb-Threatening Ischemia →